Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 5.08%
As of Tuesday, July 21, MAIA Biotechnology, Inc.’s MAIA share price has surged by 5.08%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Commentary & Analysis
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Down 5.78%
As of Thursday, July 16, MAIA Biotechnology, Inc.’s MAIA share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Michael Rose
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 5.43%
As of Wednesday, June 24, MAIA Biotechnology, Inc.’s MAIA share price has surged by 5.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Down 8.00%
As of Friday, June 05, MAIA Biotechnology, Inc.’s MAIA share price has dipped by 8.00%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Down 11.00%
As of Friday, June 05, MAIA Biotechnology, Inc.’s MAIA share price has dipped by 11.00%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $84.5 | $292.6 | 20% |
|
| Shares Out (Mil) | 60.8 | 54.4 | 52% |
|
| Institutional Ownership | 72.3% | 93.2% | 43% |
|
| Float (Mil) | 55.6 | 40.2 | 49% |
|
| Beta | 0.25 | 0.94 | 15% |
|
| Avg Daily Volume (000s) | 284 | 544 | 49% |
|
| Price Change (52-week) |
(12.0%) | 59.7% | 34% |
|
| Growth | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (27.7%) | (10.1%) | 15% |
|
| EPS (5yr) | 14.2% | 16.0% | 54 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 34.0% | (15.6%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.130) | ($0.540) | $1.110 | |
| Month Ago EPS | ($0.120) | ($0.520) | $1.120 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.120) | ($0.520) | $1.120 | |
| Year/Year Chg | (0.8%) | (22.5%) | na | |
| Financials | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($27) | ($43) | 21% |
|
| EPS (TTM) | ($0.608) | ($1.400) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $56 | $164 | 17% |
|
| Valuation | MAIA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.09 | 2.83 | 73% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (136.7%) | (47.5%) | 4% |
|
| ROE | (218.7%) | (55.0%) | 4% |
|
| Liabilities to Assets | 26.8% | 29.6% | 18% |
|
| F-Score | 3 | 3 | 18% |
|
MAIA Biotechnology, Inc. did not pass any screens on 8/21/2026.
